Meeting
2020 ASCO Virtual Scientific Program
Prophylactic dihydropyrimidine dehydrogenase (DPYD), and reactive cytidine deaminase (CDA) testing is feasible and reduces severe toxicity in Irish patients receiving 5-fluorouracil (5-FU) based chemotherapy.
Authors
Jake Murphy
Bon Secours Hospital, Cork, Ireland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Pharmacology/Pharmacodynamics/Pharmacogenetics
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3600)
DOI
10.1200/JCO.2020.38.15_suppl.3600
Abstract #
3600
Poster Bd #
330
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.
First Author: Jai Narendra Patel
Poster
2021 ASCO Quality Care Symposium
Sustainability and clinical outcomes of routine screening for pathogenic DPYD gene variants prior to fluoropyrimidine (FP) chemotherapy for gastrointestinal (GI) cancer.
First Author: Gabriel A. Brooks
Poster
2021 ASCO Annual Meeting
Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.
First Author: Côme De Metz
Poster
2019 Gastrointestinal Cancers Symposium
Identifying the importance of integrating routine pharmacogenomic testing for UGT1A1 and DPYD/tyms genetic variants in patients receiving irinotecan and/or 5-fluorouracil chemotherapy.
First Author: Candice Baldeo